FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Wolfgang Kern

Research Profile

Disorders

Procedures

Chemicals & Drugs

Physiology

Mutation

Concepts & Ideas

Living Beings

Young Adult

Co-author Network

Publications

TOP 3
Vera Grossmann; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; Alexander Kohlmann; Niroshan Nadarajah; Andreas Roller; Christiane Eder; Annette Fasan; Elisa Stopp; Sandra Weissmann; Susanne Schnittger
CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
Verena Patterer; Susanne Schnittger; Torsten Haferlach; Wolfgang Kern; Claudia Haferlach
Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
Wolfgang Kern; Susanne Schnittger; Tamara Alpermann; Ulrike Bacher; Claudia Haferlach; Torsten Haferlach
Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Wolfgang Kern (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Vera Grossmann; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; Alexander Kohlmann; Niroshan Nadarajah; Andreas Roller; Christiane Eder; Annette Fasan; Elisa Stopp; Sandra Weissmann; Susanne Schnittger
CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
British journal of haematology 2013;161(5):649-58.
2013: Verena Patterer; Susanne Schnittger; Torsten Haferlach; Wolfgang Kern; Claudia Haferlach
Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
Annals of hematology 2013;92(6):759-69.
2013: Wolfgang Kern; Susanne Schnittger; Tamara Alpermann; Ulrike Bacher; Claudia Haferlach; Torsten Haferlach
Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms.
Cytometry. Part B, Clinical cytometry 2013;84(3):194-7.
2013: Vera Grossmann; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; Franziska Poetzinger; Andreas Roller; Sonja Schindela; Susanne Schnittger; Kathrin Stadler; Sandra Weissmann; Frauke Bellos; Alexander Kohlmann
The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.
Genes, chromosomes & cancer 2013;52(4):410-22.
2013: Tamara Alpermann; Claudia Haferlach; Wolfgang Kern; Karl-Anton Kreuzer; Hermann Josef Pielken; Christoph Schmid; Norbert Schmitz; Susanne Schnittger; Hubert Serve; Clemens-Martin Wendtner; Torsten Haferlach
Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia.
Leukemia research 2013;37(2):197-200.
2013: Ulrike Bacher; Torsten Haferlach; Wolfgang Kern; Susanne Schnittger; T Alpermann; Claudia Haferlach
Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype.
Leukemia 2013;27(2):496-500.
2013: A Fasan; V Grossmann; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; Alexander Kohlmann; Frank Dicker; C Eder; Susanne Schnittger
GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.
Leukemia 2013;27(2):482-5.
2013: Annette Fasan; Vera Grossmann; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; Alexander Kohlmann; Andreas Roller; Tamara Alpermann; Christiane Eder; Susanne Schnittger
Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases.
PloS one 2013;8(2):e54365.
2013: Susanne Schnittger; P Staib; H-E Wichmann; T Alpermann; C Eder; A Fasan; V Grossmann; Claudia Haferlach; T Illig; S Jeromin; Wolfgang Kern; N Klopp; Alexander Kohlmann; K-A Kreuzer; Rudolf Peceny; C Schmid; Norbert Schmitz; Torsten Haferlach
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.
Leukemia 2013;27(1):82-91.
2013: A Fasan; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; T Alpermann; Susanne Schnittger
A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98-NSD1 fusion gene.
Leukemia 2013;27(1):245-8.
2012: Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; Alexander Kohlmann; Sonja Schindela; Ulrike Bacher; Vera Grossmann; Melanie Zenger; Susanne Schnittger
Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
Genes, chromosomes & cancer 2012;51(12):1079-85.
2012: Susanne Schnittger; Madlen Ulke; Tamara Alpermann; Ulrike Bacher; Frank Dicker; Christiane Eder; Vera Grossmann; Claudia Haferlach; Wolfgang Kern; Alexander Kohlmann; Andreas Kowarsch; Andreas Reiter; Torsten Haferlach
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.
Haematologica 2012;97(12):1890-4.
2012: Manja Meggendorfer; Seishi Ogawa; Andreas Roller; Kenichi Yoshida; Tamara Alpermann; Frank Dicker; Christiane Eder; Vera Grossmann; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; H Phillip Koeffler; Alexander Kohlmann; Susanne Schnittger
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).
Blood 2012;120(15):3080-8.
2012: Vera Grossmann; Frank Dicker; Christiane Eder; Torsten Haferlach; Wolfgang Kern; Alexander Kohlmann; Karl-Anton Kreuzer; Andreas Roller; Christoph Schmid; Susanne Schnittger; Hubert Serve; Peter Staib; Clemens-Martin Wendtner; Claudia Haferlach
A novel hierarchical prognostic model of AML solely based on molecular mutations.
Blood 2012;120(15):2963-72.
2012: Susanne Schnittger; Wolfgang Kern; Tamara Alpermann; Ulrike Bacher; Claudia Haferlach; Torsten Haferlach
Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data.
Genes, chromosomes & cancer 2012;51(10):910-24.
2012: Susanne Schnittger; Wolfgang Kern; Alexander Kohlmann; Tamara Alpermann; Ulrike Bacher; Frank Dicker; Christiane Eder; Vera Grossmann; Claudia Haferlach; Torsten Haferlach
Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow.
Haematologica 2012;97(10):1582-5.
2012: Frauke Bellos; Elena Gouberman; Claudia Haferlach; Torsten Haferlach; Tamara Alpermann; Susanne Schnittger; Wolfgang Kern
Evaluation of flow cytometric assessment of myeloid nuclear differentiation antigen expression as a diagnostic marker for myelodysplastic syndromes in a series of 269 patients.
Cytometry. Part B, Clinical cytometry 2012;82(5):295-304.
2012: Vera Grossmann; Tamara Alpermann; Valentina Artusi; Ulrike Bacher; Martin Dugas; Torsten Haferlach; Wolfgang Kern; Hans-Ulrich Klein; Alexander Kohlmann; Susanne Schnittger; Claudia Haferlach
EZH2 mutations and their association with PICALM-MLLT10 positive acute leukaemia.
British journal of haematology 2012;157(3):387-90.
2012: Wolfgang Kern; Susanne Schnittger; Tamara Alpermann; Ulrike Bacher; Frank Dicker; Claudia Haferlach; Torsten Haferlach
Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia.
Cytometry. Part B, Clinical cytometry 2012;82(3):145-50.
2012: S Weissmann; A Kowarsch; N Nadarajah; Susanne Schnittger; T Alpermann; Frank Dicker; C Eder; A Fasan; V Grossmann; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; Alexander Kohlmann
Landscape of TET2 mutations in acute myeloid leukemia.
Leukemia 2012;26(5):934-42.
2012: Claudia Haferlach; Tamara Alpermann; Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Melanie Zenger; Torsten Haferlach
ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Genes, chromosomes & cancer 2012;51(4):328-37.
2012: Claudia Haferlach; V Grossmann; Wolfgang Kern; A Kohlmann; S Schindela; Susanne Schnittger; Torsten Haferlach
Deletion of the tumor-suppressor gene NF1 occurs in 5% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the cases.
Leukemia 2012;26(4):834-9.
2012: Susanne Schnittger; Madlen Ulke; Nicole Wendland; Ulrike Bacher; Frank Dicker; Vera Grossmann; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern
Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia.
Blood 2012;119(13):3151-4.
2012: Claudia Haferlach; Tamara Alpermann; Jörg Chromik; Heinz-Gert Höffkes; Wolfgang Kern; Karl-Anton Kreuzer; Hermann Josef Pielken; Christoph Schmid; Susanne Schnittger; Torsten Haferlach
Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype.
Blood 2012;119(9):2122-5.
2011: Susanne Schnittger; Wolfgang Kern; T Alpermann; Ulrike Bacher; Claudia Haferlach; Torsten Haferlach
Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.
Leukemia 2011;25(8):1297-304.
2011: V Grossmann; A Kohlmann; C Eder; Claudia Haferlach; Wolfgang Kern; N C P Cross; Torsten Haferlach; Susanne Schnittger
Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance.
Leukemia 2011;25(5):877-9.
2011: Claudia Haferlach; Ulrike Bacher; Torsten Haferlach; Frank Dicker; T Alpermann; Wolfgang Kern; Susanne Schnittger
The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML.
Leukemia 2011;25(5):874-7.
2011: V Grossmann; A Kohlmann; H-U Klein; S Schindela; Susanne Schnittger; Frank Dicker; M Dugas; Wolfgang Kern; Torsten Haferlach; Claudia Haferlach
Targeted next-generation sequencing detects point mutations, insertions, deletions and balanced chromosomal rearrangements as well as identifies novel leukemia-specific fusion genes in a single procedure.
Leukemia 2011;25(4):671-80.
2011: Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; T Alpermann; Frank Dicker; J Sundermann; Wolfgang Kern; Torsten Haferlach
Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
Leukemia 2011;25(4):615-21.
2011: J Flach; Frank Dicker; Susanne Schnittger; S Schindela; A Kohlmann; Torsten Haferlach; Wolfgang Kern; Claudia Haferlach
An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling.
Leukemia 2011;25(4):713-8.
2011: Vera Grossmann; Susanne Schnittger; Sonja Schindela; Hans-Ulrich Klein; Christiane Eder; Martin Dugas; Wolfgang Kern; Torsten Haferlach; Claudia Haferlach; Alexander Kohlmann
Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology.
The Journal of molecular diagnostics : JMD 2011;13(2):129-36.
2011: V Grossmann; A Kohlmann; M Zenger; S Schindela; C Eder; S Weissmann; Susanne Schnittger; Wolfgang Kern; M C Müller; A Hochhaus; Torsten Haferlach; Claudia Haferlach
A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases.
Leukemia 2011;25(3):557-60.
2011: Susanne Schnittger; Frank Dicker; Wolfgang Kern; Nicole Wendland; Jana Sundermann; Tamara Alpermann; Claudia Haferlach; Torsten Haferlach
RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis.
Blood 2011;117(8):2348-57.
2011: Wolfgang Kern; Ulrike Bacher; Claudia Haferlach; Susanne Schnittger; Torsten Haferlach
Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells.
Leukemia & lymphoma 2011;52(1):92-100.
2011: Susanne Schnittger; Ulrike Bacher; Christiane Eder; Peter Lohse; Claudia Haferlach; Wolfgang Kern; Torsten Haferlach
A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls.
Experimental hematology 2011;39(1):87-94.
2010: Miriam Miesner; Claudia Haferlach; Ulrike Bacher; Tamara Weiss; Katja Macijewski; Alexander Kohlmann; Hans-Ulrich Klein; Martin Dugas; Wolfgang Kern; Susanne Schnittger; Torsten Haferlach
Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
Blood 2010;116(15):2742-51.
2010: Wolfgang Kern; Claudia Haferlach; Susanne Schnittger; Torsten Haferlach
Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data.
Cancer 2010;116(19):4549-63.
2010: Claudia Haferlach; Frank Dicker; Tamara Weiss; Susanne Schnittger; Christian Beck; Albert Grote-Metke; Daniel Oruzio; Wolfgang Kern; Torsten Haferlach
Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters.
Genes, chromosomes & cancer 2010;49(9):851-9.
2010: Alexander Kohlmann; Vera Grossmann; Hans-Ulrich Klein; Sonja Schindela; Tamara Weiss; Beray Kazak; Frank Dicker; Susanne Schnittger; Martin Dugas; Wolfgang Kern; Claudia Haferlach; Torsten Haferlach
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3858-65.
2009: Jan Braess; Karsten Spiekermann; Peter Staib; Andreas Grüneisen; Bernhard Wörmann; Wolf-Dieter Ludwig; Hubert Serve; Albrecht Reichle; Rudolf Peceny; Daniel Oruzio; Christoph Schmid; Xaver Schiel; Marcus Hentrich; Christina Sauerland; Michael Unterhalt; Michael Fiegl; Wolfgang Kern; Christian Buske; Stefan Bohlander; Achim Heinecke; Herrad Baurmann; Dietrich W Beelen; Wolfgang E Berdel; Thomas Büchner; Wolfgang Hiddemann
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.
Blood 2009;113(17):3903-10.
2009: Thomas Büchner; Wolfgang E Berdel; Claudia Haferlach; Torsten Haferlach; Susanne Schnittger; Carsten Müller-Tidow; Jan Braess; Karsten Spiekermann; Joachim Kienast; Peter Staib; Andreas Grüneisen; Wolfgang Kern; Albrecht Reichle; Georg Maschmeyer; Carlo Aul; Eva Lengfelder; Maria Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Wolfgang Hiddemann
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(1):61-9.
2006: Ulrike Bacher; Susanne Schnittger; Wolfgang Kern; Guido Trenn; Martin Weisser; Torsten Haferlach; Claudia Schoch
Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22).
Cancer genetics and cytogenetics 2006;168(2):172-4.
2006: Ulrike Bacher; Andreas Reiter; Torsten Haferlach; Lothar Mueller; Susanne Schnittger; Wolfgang Kern; Claudia Schoch
A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia.
Haematologica 2006;91(6):817-20.
2006: Thomas Büchner; Wolfgang E Berdel; Claudia Schoch; Torsten Haferlach; Hubert Serve; Joachim Kienast; Susanne Schnittger; Wolfgang Kern; Joëlle Tchinda; Albrecht Reichle; Eva Lengfelder; Peter Staib; Wolf-Dieter Ludwig; Carlo Aul; Hartmut Eimermacher; Leopold Balleisen; Maria Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Wolfgang Hiddemann
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2480-9.
2006: Susanne Schnittger; Tobias M Kohl; Nina Leopold; Claudia Schoch; H-Erich Wichmann; Wolfgang Kern; Peter Lohse; Wolfgang Hiddemann; Torsten Haferlach; Karsten Spiekermann
D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias.
Genes, chromosomes & cancer 2006;45(4):332-7.
2006: Susanne Schnittger; Tobias M Kohl; Torsten Haferlach; Wolfgang Kern; Wolfgang Hiddemann; Karsten Spiekermann; Claudia Schoch
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.
Blood 2006;107(5):1791-9.
2006: Ulrike Bacher; Wolfgang Kern; Claudia Schoch; Susanne Schnittger; Wolfgang Hiddemann; Torsten Haferlach
Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia.
Cancer 2006;106(4):839-47.
2006: Alexander Kohlmann; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach
Classification of AML by DNA-oligonucleotide microarrays.
Methods in molecular medicine 2006;125():213-40.
2005: Florian Kuchenbauer; Wolfgang Kern; Claudia Schoch; Alexander Kohlmann; Wolfgang Hiddemann; Torsten Haferlach; Susanne Schnittger
Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Haematologica 2005;90(12):1617-25.
2005: Susanne Schnittger; Claudia Schoch; Wolfgang Kern; Cristina Mecucci; Claudia Tschulik; Massimo F Martelli; Torsten Haferlach; Wolfgang Hiddemann; Brunangelo Falini
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.
Blood 2005;106(12):3733-9.
2005: Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Wolfgang Hiddemann; Torsten Haferlach; Claudia Schoch
Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia.
Haematologica 2005;90(11):1502-10.
2005: Thomas Büchner; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Torsten Haferlach; Susanne Schnittger; Wolfgang Kern; Carlo Aul; Eva Lengfelder; Andrea Schumacher; Albrecht Reichle; Peter Staib; Leopold Balleisen; Hartmut Eimermacher; Andreas Grüneisen; Herbert Rasche; Maria Cristina Sauerland; Achim Heinecke; Rolf M Mesters; Hubert Serve; Joachim Kienast; Wolfgang Hiddemann
Treatment of older patients with AML.
Critical reviews in oncology/hematology 2005;56(2):247-59.
2005: Torsten Haferlach; Wolfgang Kern; Susanne Schnittger; Claudia Schoch
Modern diagnostics in acute leukemias.
Critical reviews in oncology/hematology 2005;56(2):223-34.
2005: Wolfgang Kern; Claudia Schoch; Torsten Haferlach; Susanne Schnittger
Monitoring of minimal residual disease in acute myeloid leukemia.
Critical reviews in oncology/hematology 2005;56(2):283-309.
2005: Wolfgang Hiddemann; Karsten Spiekermann; Christian Buske; Michaela Feuring-Buske; Jan Braess; Torsten Haferlach; Claudia Schoch; Wolfgang Kern; Susanne Schnittger; Wolfgang E Berdel; Bernhard Wörmann; Achim Heinecke; Cristina Sauerland; Thomas Büchner
Towards a pathogenesis-oriented therapy of acute myeloid leukemia.
Critical reviews in oncology/hematology 2005;56(2):235-45.
2005: Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Wolfgang Hiddemann; Claudia Schoch; Torsten Haferlach
Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients.
Annals of hematology 2005;84(12):785-91.
2005: Torsten Haferlach; Alexander Kohlmann; Susanne Schnittger; Martin Dugas; Wolfgang Hiddemann; Wolfgang Kern; Claudia Schoch
Global approach to the diagnosis of leukemia using gene expression profiling.
Blood 2005;106(4):1189-98.
2005: Christina Schessl; Vijay P S Rawat; Monica Cusan; Aniruddha Deshpande; Tobias M Kohl; Patricia M Rosten; Karsten Spiekermann; R Keith Humphries; Susanne Schnittger; Wolfgang Kern; Wolfgang Hiddemann; Leticia Quintanilla-Martinez; Stefan K Bohlander; Michaela Feuring-Buske; Christian Buske
The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.
The Journal of clinical investigation 2005;115(8):2159-68.
2005: Martin Weisser; Wolfgang Kern; S Rauhut; Claudia Schoch; Wolfgang Hiddemann; Torsten Haferlach; Susanne Schnittger
Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.
Leukemia 2005;19(8):1416-23.
2005: Florian Kuchenbauer; Claudia Schoch; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach; Susanne Schnittger
Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia.
British journal of haematology 2005;130(2):196-202.
2005: Martin Weisser; Wolfgang Kern; Claudia Schoch; Wolfgang Hiddemann; Torsten Haferlach; Susanne Schnittger
Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy.
Haematologica 2005;90(7):881-9.
2005: Claudia Schoch; Alexander Kohlmann; Martin Dugas; Wolfgang Kern; Wolfgang Hiddemann; Susanne Schnittger; Torsten Haferlach
Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q.
Leukemia 2005;19(7):1224-8.
2005: Wolfgang Kern; Alexander Kohlmann; Susanne Schnittger; Claudia Schoch; Torsten Haferlach
Role of gene expression profiling for diagnosing acute leukemias.
Reviews in clinical and experimental hematology 2005;9(1):E1.
2005: Alexander Kohlmann; Claudia Schoch; Martin Dugas; Susanne Schnittger; Wolfgang Hiddemann; Wolfgang Kern; Torsten Haferlach
New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes.
Leukemia 2005;19(6):953-64.
2005: Ulrike Bacher; Torsten Haferlach; Wolfgang Kern; Wolfgang Hiddemann; Susanne Schnittger; Claudia Schoch
Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.
Annals of hematology 2005;84(4):250-7.
2005: Wolfgang Kern; Torsten Haferlach; Susanne Schnittger; Claudia Schoch
Detection of t(14;18)(q32;q21) in B-cell chronic lymphocytic leukemia.
Archives of pathology & laboratory medicine 2005;129(3):410-1.
2005: Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Wolfgang Hiddemann; Claudia Schoch; Torsten Haferlach
Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia.
Leukemia & lymphoma 2005;46(3):357-66.
2005: Ulrike Bacher; Torsten Haferlach; Wolfgang Hiddemann; Susanne Schnittger; Wolfgang Kern; Claudia Schoch
Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression.
Cancer genetics and cytogenetics 2005;157(1):53-61.
2005: Thomas Buechner; Wolfgang E Berdel; Claudia Schoch; Torsten Haferlach; Hubert Serve; Susanne Schnittger; Wolfgang Kern; Joëlle Tchinda; Albrecht Reichle; Peter Staib; Wolf-Dieter Ludwig; Carlo Aul; Maria Cristina Sauerland; Achim Heinecke; Bernhard Woermann; Wolfgang Hiddemann
Treatment of AML in biological subgroups.
Hematology (Amsterdam, Netherlands) 2005;10 Suppl 1():281-85.
2004: Wolfgang Kern; Daniela Voskova; Claudia Schoch; Wolfgang Hiddemann; Susanne Schnittger; Torsten Haferlach
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.
Blood 2004;104(10):3078-85.
2004: Daniela Voskova; Claudia Schoch; Susanne Schnittger; Wolfgang Hiddemann; Torsten Haferlach; Wolfgang Kern
Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.
Cytometry. Part B, Clinical cytometry 2004;62(1):25-38.
2004: Claudia Schoch; Wolfgang Kern; Susanne Schnittger; Thomas Büchner; Wolfgang Hiddemann; Torsten Haferlach
The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
Haematologica 2004;89(9):1082-90.
2004: Ulrike Bacher; Wolfgang Kern; Claudia Schoch; Wolfgang Hiddemann; Torsten Haferlach
Discrimination of chronic lymphocytic leukemia (CLL) and CLL/PL by cytomorphology can clearly be correlated to specific genetic markers as investigated by interphase fluorescence in situ hybridization (FISH).
Annals of hematology 2004;83(6):349-55.
2004: Wolfgang Kern; Daniela Voskova; Claudia Schoch; Susanne Schnittger; Wolfgang Hiddemann; Torsten Haferlach
Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.
Haematologica 2004;89(5):528-40.
2004: Torsten Haferlach; Wolfgang Kern; Claudia Schoch; Susanne Schnittger; Maria Cristina Sauerland; Achim Heinecke; Thomas Büchner; Wolfgang Hiddemann
A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
Haematologica 2004;89(4):408-18.
2004: Wolfgang Kern; Daniela Voskova; Susanne Schnittger; Claudia Schoch; Wolfgang Hiddemann; Torsten Haferlach
Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(5):410-8.
2004: Wolfgang Kern; Alexander Kohlmann; Susanne Schnittger; Wolfgang Hiddemann; Claudia Schoch; Torsten Haferlach
Gene expression profiling as a diagnostic tool in acute myeloid leukemia.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 2004;4(4):225-37.
2004: Susanne Schnittger; Claudia Schoch; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach
FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia.
Acta haematologica 2004;112(1-2):68-78.
2004: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Christa Fonatsch; Helmut Löffler; Torsten Haferlach; Wolf-Dieter Ludwig; Georg Maschmeyer; Peter Staib; Leopold Balleisen; Andreas Grüneisen; Carlo Aul; Eva Lengfelder; Rüdiger Hehlmann; Wolfgang Kern; Hubert Serve; Rolf M Mesters; Hartmut Eimermacher; Norbert Frickhofen; Joachim Kienast; A Giagounidis; Maria Cristina Sauerland; Achim Heinecke
Subgroup specific therapy effects in AML: AMLCG data.
Annals of hematology 2004;83 Suppl 1():S100-1.
2004: Torsten Haferlach; Wolfgang Kern; Susanne Schnittger; Claudia Schoch
Modern diagnostics in chronic myeloproliferative diseases (CMPDs).
Annals of hematology 2004;83 Suppl 1():S59-61.
2004: Wolfgang Hiddemann; Wolfgang Kern; Achim Heinecke; Cristina Sauerland; Thomas Büchner
Priming with G-CSF in acute myeloid leukemia: preliminary data of the AMLCG.
Annals of hematology 2004;83 Suppl 1():S53-4.
2004: Alexander Kohlmann; Claudia Schoch; Susanne Schnittger; Martin Dugas; Wolfgang Hiddemann; Wolfgang Kern; Torsten Haferlach
Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients.
Leukemia 2004;18(1):63-71.
2004: Claudia Schoch; Wolfgang Kern; Susanne Schnittger; Wolfgang Hiddemann; Torsten Haferlach
Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
Leukemia 2004;18(1):120-5.
2003: Thomas Büchner; Wolfgang Hiddemann; Wolfgang E Berdel; Bernhard Wörmann; Claudia Schoch; Christa Fonatsch; Helmut Löffler; Torsten Haferlach; Wolf-Dieter Ludwig; Georg Maschmeyer; Peter Staib; Carlo Aul; Andreas Gruneisen; Eva Lengfelder; Norbert Frickhofen; Wolfgang Kern; Hubert Serve; Rolf M Mesters; Maria Cristina Sauerland; Achim Heinecke
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4496-504.
2003: Susanne Schnittger; Martin Weisser; Claudia Schoch; Wolfgang Hiddemann; Torsten Haferlach; Wolfgang Kern
New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.
Blood 2003;102(8):2746-55.
2003: Torsten Haferlach; Alexander Kohlmann; Wolfgang Kern; Wolfgang Hiddemann; Susanne Schnittger; Claudia Schoch
Gene expression profiling as a tool for the diagnosis of acute leukemias.
Seminars in hematology 2003;40(4):281-95.
2003: Georg Lenz; Ulrich T Hacker; Wolfgang Kern; Andreas Schalhorn; Wolfgang Hiddemann
Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution.
Anti-cancer drugs 2003;14(9):731-3.
2003: Claudia Schoch; Susanne Schnittger; Mirjam Klaus; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach
AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases.
Blood 2003;102(7):2395-402.
2003: Wolfgang Kern; Alexander Kohlmann; Christian Wuchter; Susanne Schnittger; Claudia Schoch; Susanne Mergenthaler; Richard Ratei; Wolf-Dieter Ludwig; Wolfgang Hiddemann; Torsten Haferlach
Correlation of protein expression and gene expression in acute leukemia.
Cytometry. Part B, Clinical cytometry 2003;55(1):29-36.
2003: Wolfgang Kern; Susanne Schnittger
Monitoring of acute myeloid leukemia by flow cytometry.
Current oncology reports 2003;5(5):405-12.
2003: Alexander Kohlmann; Claudia Schoch; Susanne Schnittger; Martin Dugas; Wolfgang Hiddemann; Wolfgang Kern; Torsten Haferlach
Molecular characterization of acute leukemias by use of microarray technology.
Genes, chromosomes & cancer 2003;37(4):396-405.
2003: Wolfgang Kern; Susanne Danhauser-Riedl; Richard Ratei; Susanne Schnittger; Claudia Schoch; Hans-Jochem Kolb; Wolf-Dieter Ludwig; Wolfgang Hiddemann; Torsten Haferlach
Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.
Haematologica 2003;88(6):646-53.
2003: Torsten Haferlach; Claudia Schoch; Helmut Löffler; Winfried Gassmann; Wolfgang Kern; Susanne Schnittger; Christa Fonatsch; Wolf-Dieter Ludwig; Christian Wuchter; Brigitte Schlegelberger; Peter Staib; Albrecht Reichle; Uschi Kubica; Hartmut Eimermacher; Leopold Balleisen; Andreas Grüneisen; Detlef Haase; Carlo Aul; Jochen Karow; Eva Lengfelder; Bernhard Wörmann; Achim Heinecke; Maria Cristina Sauerland; Thomas Büchner; Wolfgang Hiddemann
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):256-65.
2003: Wolfgang Kern; Torsten Haferlach; Claudia Schoch; Helmut Loffler; Winfried Gassmann; Achim Heinecke; Maria Cristina Sauerland; Wolfgang E Berdel; Thomas Buchner; Wolfgang Hiddemann
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Blood 2003;101(1):64-70.
2002: Wolfgang Kern; Torsten Haferlach; Susanne Schnittger; W D Ludwig; Wolfgang Hiddemann; Claudia Schoch
Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy.
Leukemia 2002;16(10):2084-91.
2002: Wolfgang Kern; Jan Braess; Marion Kotschofsky; Stefan Samel; Heinz Becker; Wolfgang Hiddemann; Eberhard Schleyer
Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
Anticancer research 2002;22(5):3099-102.
2002: Claudia Schoch; Torsten Haferlach; Sabina Bursch; Daniela Gerstner; Susanne Schnittger; Martin Dugas; Wolfgang Kern; Helmut Löffler; Wolfgang Hiddemann
Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH.
Genes, chromosomes & cancer 2002;35(1):20-9.
2002: Claudia Schoch; Alexander Kohlmann; Susanne Schnittger; Benedikt Brors; Martin Dugas; Susanne Mergenthaler; Wolfgang Kern; Wolfgang Hiddemann; Roland Eils; Torsten Haferlach
Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(15):10008-13.
2002: Susanne Schnittger; Claudia Schoch; Martin Dugas; Wolfgang Kern; Peter Staib; Christian Wuchter; Helmut Löffler; Cristina Sauerland; Hubert Serve; Thomas Büchner; Torsten Haferlach; Wolfgang Hiddemann
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
Blood 2002;100(1):59-66.
2002: Martin Dugas; Claudia Schoch; Susanne Schnittger; Alexander Kohlmann; Wolfgang Kern; Torsten Haferlach; Karl Uberla
Impact of integrating clinical and genetic information.
In silico biology 2002;2(3):383-91.
2002: Claudia Schoch; Susanne Schnittger; Wolfgang Kern; Eva Lengfelder; Helmut Löffler; Wolfgang Hiddemann; Torsten Haferlach
Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemia.
The hematology journal : the official journal of the European Haematology Association / EHA 2002;3(5):259-63.
2001: Wolfgang Kern; Eberhard Schleyer; Jan Braess; E Wittmer; J Ohnesorge; Michael Unterhalt; B Wörmann; T Büchner; Wolfgang Hiddemann
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Annals of hematology 2001;80(6):334-9.
2001: Jan Braess; G Jahns-Streubel; Claudia Schoch; Detlef Haase; Torsten Haferlach; Michael Fiegl; S Voss; Wolfgang Kern; Eberhard Schleyer; Wolfgang Hiddemann
Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia.
British journal of haematology 2001;113(4):975-82.
2001: Wolfgang Kern; B Beckert; N Lang; J Stemmler; M Beykirch; J Stein; E Goecke; Tobias Waggershauser; Jan Braess; Andreas Schalhorn; Wolfgang Hiddemann
Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(5):599-603.
2001: Claudia Schoch; Sabina Bursch; Wolfgang Kern; Susanne Schnittger; Wolfgang Hiddemann; Torsten Haferlach
Gain of an isochromosome 5p: a new recurrent chromosome abnormality in acute monoblastic leukemia.
Cancer genetics and cytogenetics 2001;127(1):85-8.
2001: Wolfgang Kern; Jan Braess; S Friedrichsen; Cornelia C Kaufmann; Eberhard Schleyer; Wolfgang Hiddemann
Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve.
Journal of cancer research and clinical oncology 2001;127(1):64-8.
2000: Wolfgang Kern; B Beckert; N Lang; Tobias Waggershauser; Jan Braess; Andreas Schalhorn; Wolfgang Hiddemann
Hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer: role of carcino-embryonic antigen in assessment of response.
Anticancer research 2000;20(6D):4973-5.
2000: Wolfgang Kern; Jan Braess; Cornelia C Kaufmann; S Wilde; Eberhard Schleyer; Wolfgang Hiddemann
Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection.
Anticancer research 2000;20(5C):3679-88.
2000: Jan Braess; S Voss; G Jahns-Streubel; Claudia Schoch; Torsten Haferlach; Wolfgang Kern; S Keye; Eberhard Schleyer; Wolfgang Hiddemann
The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity.
British journal of haematology 2000;110(1):170-9.
2000: Jan Braess; C Wegendt; G Jahns-Streubel; Wolfgang Kern; S Keye; Michael Unterhalt; Eberhard Schleyer; Wolfgang Hiddemann
Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
British journal of haematology 2000;109(2):388-95.
2000: Wolfgang Kern; C Schoch; T Haferlach; Jan Braess; Michael Unterhalt; B Wörmann; T Büchner; Wolfgang Hiddemann
Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities.
Leukemia 2000;14(2):226-31.
1999: Jan Braess; C Wegendt; Michaela Feuring-Buske; Joachim Riggert; Wolfgang Kern; Wolfgang Hiddemann; Eberhard Schleyer
Leukaemic blasts differ from normal bone marrow mononuclear cells and CD34+ haemopoietic stem cells in their metabolism of cytosine arabinoside.
British journal of haematology 1999;105(2):388-93.
1999: Wolfgang Kern; Jan Braess; B Böttger; Cornelia C Kaufmann; Wolfgang Hiddemann; Eberhard Schleyer
Oxaliplatin pharmacokinetics during a four-hour infusion.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(4):761-5.
1998: Jan Braess; Mathias Freund; A Hanauske; G Heil; C Kaufmann; Wolfgang Kern; M Schüssler; Wolfgang Hiddemann; Eberhard Schleyer
Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics.
Leukemia 1998;12(10):1618-26.
1998: Wolfgang Kern; Jan Braess; A Grote-Metke; H Kuse; R Fuchs; Dieter K Hossfeld; Albrecht Reichle; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: results of a prospective multicenter phase II trial. German AML Cooperative Group.
Leukemia 1998;12(10):1522-6.
1998: Wolfgang Kern; Carlo Aul; Georg Maschmeyer; R Kuse; A Kerkhoff; A Grote-Metke; Hartmut Eimermacher; Uschi Kubica; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative Group.
Annals of hematology 1998;77(3):115-22.
1998: Wolfgang Kern; G Behre; T Rudolf; A Kerkhoff; A Grote-Metke; Hartmut Eimermacher; Uschi Kubica; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
Cancer 1998;83(2):291-301.
1998: Wolfgang Kern; Carlo Aul; Georg Maschmeyer; R Schönrock-Nabulsi; Wolf-Dieter Ludwig; A Bartholomäus; P Bettelheim; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
Leukemia 1998;12(7):1049-55.
1998: Wolfgang Kern; Jan Braess; H Bertz; Christiane Pott; Eberhard Schleyer; J Finke; Reinhard Rüchel; Wolfgang Hiddemann
Chronic systemic aspergillosis in a patient with acute myeloid leukemia.
Annals of hematology 1998;76(3-4):175-7.
1997: Eberhard Schleyer; S Kühn; H Rührs; Michael Unterhalt; Cornelia C Kaufmann; Wolfgang Kern; Jan Braess; G Sträubel; Wolfgang Hiddemann
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Leukemia 1997;11 Suppl 5():S15-21.
1997: Tobias J. Legler; I Fischer; J Dittmann; G Simson; Rainer Lynen; Andreas Humpe; Joachim Riggert; Eberhard Schleyer; Wolfgang Kern; Wolfgang Hiddemann; Michael Köhler
Frequency and causes of refractoriness in multiply transfused patients.
Annals of hematology 1997;74(4):185-9.
1997: Wolfgang Kern; Eberhard Schleyer; Michael Unterhalt; Bernhard Wörmann; Thomas Büchner; Wolfgang Hiddemann
High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
Cancer 1997;79(1):59-68.
1996: Jan Braess; Wolfgang Kern; Michael Unterhalt; Cornelia C Kaufmann; B Ramsauer; M Schüssler; A Kaeser-Fröhlich; Wolfgang Hiddemann; Eberhard Schleyer
Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone.
Annals of hematology 1996;73(4):201-4.
1996: Wolfgang Hiddemann; Eberhard Schleyer; Michael Unterhalt; Wolfgang Kern; Thomas Büchner
Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells.
Therapeutic drug monitoring 1996;18(4):341-9.
1996: Eberhard Schleyer; S Kühn; H Rührs; Michael Unterhalt; Cornelia C Kaufmann; Wolfgang Kern; Jan Braess; G Sträubel; Wolfgang Hiddemann
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Leukemia 1996;10(4):707-12.
1991: Wolfgang Kern
Infectious diseases as a clinical specialty in Germany--fact or fancy?
Infection 1991;19(1):1-6.
1988: Wolfgang Kern; H Gulden; E Vanek; E Kurrle
In vitro antibacterial activity of imipenem in combination with newer quinolone derivatives.
Chemotherapy 1988;34(2):117-26.
1988: T Schmeiser; E Kurrle; Rudolf Arnold; Markus Wiesneth; Donald Bunjes; B Hertenstein; Wolfgang Kern; W Heit; H Heimpel
Norfloxacin for prevention of bacterial infections during severe granulocytopenia after bone marrow transplantation.
Scandinavian journal of infectious diseases 1988;20(6):625-31.
1987: Wolfgang Kern; E Vanek
Aerococcus bacteremia associated with granulocytopenia.
European journal of clinical microbiology 1987;6(6):670-3.
1987: Wolfgang Kern; E Kurrle; E Vanek
Ofloxacin for prevention of bacterial infections in granulocytopenic patients.
Infection 1987;15(6):427-33.
1987: Wolfgang Kern; S Mayer; P Kreuzer; E Vanek
Low prevalence of intestinal cryptosporidiosis among immunocompetent and immunocompromised patients with and without diarrhoea in southern Germany.
Infection 1987;15(6):440-3.
1987: Wolfgang Kern; C Kirsten; P Förster; HJ Diesfeld; E Vanek
Specificity of routine parasite serological tests in autoimmune disorders, neoplastic disease, EBV-induced mononucleosis, and HIV infection.
Klinische Wochenschrift 1987;65(19):898-905.
1987: Wolfgang Kern; B Anger; W Haerer; E Vanek; H Heimpel
[Endocarditis caused by Haemophilus parainfluenzae and Neisseria gonorrhoeae].
Immunität und Infektion 1987;15(5):165-72.
1987: Wolfgang Kern; E Kurrle; E Vanek
High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia.
Klinische Wochenschrift 1987;65(16):773-80.